- Home
- ARHS vs CTMX Comparison
ARHS vs CTMX Comparison
Compare ARHS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | CTMX |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 977.1M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ARHS | CTMX |
|---|---|---|
| Price | $6.75 | $3.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | $10.78 | ★ $12.10 |
| AVG Volume (30 Days) | 1.6M | ★ 2.9M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,379,222,000.00 | $76,201,000.00 |
| Revenue This Year | $7.23 | N/A |
| Revenue Next Year | $7.10 | $7.61 |
| P/E Ratio | $343.00 | ★ $22.58 |
| Revenue Growth | ★ 8.51 | N/A |
| 52 Week Low | $5.57 | $1.72 |
| 52 Week High | $12.97 | $8.21 |
Technical Indicators
Market Signals| Indicator | ARHS | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 36.09 |
| Support Level | $6.17 | $3.40 |
| Resistance Level | $7.62 | $3.91 |
| Average True Range (ATR) | 0.31 | 0.18 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 87.78 | 21.58 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.